http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Tenofovir (TDF) therapy has been recommended as a rescue strategy for chronic hepatitis B (CHB) patients with nucleos(t)ide (NA) resistance. Unfortunately, after sequential NA monotherapy in CHB patients with lamivudine (LAM) resistance, multidrug resistance (MDR) developed in a substantial number of patients. Very limited data are available on the comparison of TDF therapy between single drug resistant (SDR) and MDR groups in NA-resistant CHB patients. Methods: Of the 269 CHB patients with NA-resistance, 139 were SDR group and 130 were MDR group. A matched study population was constructed to compare the antiviral efficacy of TDF therapy by a propensity score analysis. Results: Two hundreds CHB patients were selected after matching propensity score with 1:1 ratio. The median follow-up period during TDF therapy was 47.3 months (range, 6-59 months). Virologic response (VR) occurred in 188 patients (95 patients in the SDR group and 93 patients in the MDR group) during the treatment period. The VR rate was lower in the MDR group than in the SDR group but statistically insignificant (74.3% vs. 85.6% at month 12, and 87.4% vs. 92.2% at month 24; log rank P=0.111). Partial virologic response (PVR) rates were not different between both groups (20.0% and 31.0% in the SDR and MDR groups, respectively; P = 0.105). The rates of ALT normalization and HBeAg seroconvesion also did not differ between both groups (P>0.05). In multivariate analysis, absolute HBV DNA level at the start of TDF rescue treatment (P<0.001; OR, 0.715; 95% CI, 0.646-0.791) was only significantly associated with VR. Conclusions: TDF rescue therapy has comparable efficacy in the SDR and MDR CHB patients, and the presence of MDR did not alter the response rates. HBV DNA level at the start of TDF rescue therapy was the only predictor of subsequent VR.
Antioxidant activity of <i>Prunus mume</i> extract in cooked chicken breast meat
Jo, Seong-Chun,Nam, Ki-Chang,Min, Byoung-Rok,Ahn, Dong-Uk,Cho, Sung-Hwan,Park, Woo-Po,Lee, Seung-Cheol Blackwell Publishing Ltd 2006 International journal of food science & technology Vol.41 No.suppl1
<P>Summary</P><P>The antioxidant properties of methanolic extracts from the fruit of <I>Prunus mume</I> were determined in chicken breast meat systems. When <I>P. mume</I> extract (PM) was added to chicken breast meat, 2-thiobarbituric acid-reactive substances (TBARS) value at day 3 was decreased by about 45% of the control. PM did not affect colour of chicken meat compared with the control. The amounts of volatile aldehydes and hydrocarbons were significantly decreased by the addition of PM. Especially, hexanal was the most predominant volatile compound in the control taking up almost more than 50% of the total volatiles and PM reduced the amount into 26% of the control meat at 3 days.</P>
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Either entecavir (ETV) or tenofovir disoproxil fumarate (TDF) are recommended to use as the first-line nucleoside analogues (NAs) in patients with chronic hepatitis B (CHB) due to their potent viral suppression with a lower risk of drug resistance and excellent preventive effect for hepatocellular carcinoma (HCC) development. However, the effects of ETV and TDF on HCC development in CHB patients have not been fully examined. Methods: The aims of the current study were therefore to compare the effects of ETV and TDF therapy on HCC development in CHB patients in clinical practice. A total of 1,412 ETV-naïve patients and 1,318 TDF-naı¨ve patients were enrolled into the study. Results: The baseline characteristics of both groups were no significant difference. Virological and biochemical responses were similar between the two therapy groups over time. During a median 26 months of follow-up (range 1.0-60 months), 126 patients (4.6%) developed HCC. The 1-, 2-, 3- and 5-year cumulative HCC incidence rates in all cases were 2.2%, 3.8%, 5.1% and 9.9%, respectively. There was no significant difference in cumulative rates of HCC carcinoma (HCC) development (log-rank P = 0.357) between the two therapy groups. Multivariate analysis showed that male, older age, cirrhosis, lower albumin levels and HBeAg-positve status were independently associated with HCC development. Conclusions: HCC incidence and virological response were similar between ETV and TDF therapy groups in CHB patients in clinical practice. Therefore, either ETV or TDF are recommended to use as the first-line nucleoside analogues in patients with CHB due to their potent viral suppression and similar effect for HCC development.
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Rare data are available on the comparison of tenofovir (TDF) and entecavir (ETV) therapy in chronic hepatitis B patients with baseline high viral load (HVL) in clinical practice, defined as having hepatitis B virus (HBV) DNA >8 log10 copies/mL (7.3 log10 IU/mL). Methods: We performed a retrospective analysis of the efficacy of TDF therapy, as compared to that of ETV therapy, in patients with HVL. A matched study population was constructed to compare the antiviral efficacy of TDF therapy and ETV therapy by a propensity score analysis. Results: Three hundreds two patients were selected after matching propensity score with 1:1 ratio. Virologic response (VR) was observed in 63.6% (96/151) of patients in the TDF group and in 64.2% (97/151) of the patients in the ETV group. The VR rates were not different between the TDF and ETV groups (51.5 vs. 51.4% at month 12, and 72.1 vs. 69.2% at month 24; log rank P = 0.432). During therapy, 70.2% of patients in the TDF group, and 74.8% of patients in the ETV group had partial VR, respectively (P=0.367). ALT normalization rates also did not differ between both the treatment groups (94.3% and 92.1% in the TDF and ETV therapy groups, respectively; P = 0.838). Nineteen patients experienced a virological breakthrough. Among them, 7 patients (4.6 %) was in the TDF group and 12 patients (7.9 %) were in the ETV group (P = 0.236). During therapy, 21.2% (28 of 132) of patients in the TDF group, and 19.1% (25 of 131) of patients in the ETV group achieved HBeAg seroconversion, respectively (P = 0.667). In multivariate analysis, absolute HBV DNA level at baseline (P<0.001), HBeAg-positive status (P< 0.001) and ALT levels at baseline (P =0.044) were significantly associated with VR. Conclusions: In patients with HVL >8 log10 copies/mL (7.3 log10 IU/mL), virological and biochemical responses were similar between ETV and TDF therapy groups in CHB patients. Therefore, either ETV or TDF are recommended to use as the first-line nucleoside analogues in patients with HVL..
Jo, Seong-Chun,Nam, Ki-Chang,Min, Byoung-Rok,Ahn, Dong-Uk,Cho, Sung-Hwan,Park, Woo-Po,Lee, Seung-Cheol The Korean Society of Food Science and Nutrition 2005 Preventive Nutrition and Food Science Vol.10 No.4
The antioxidant properties of methanolic extracts (PM) from the fruit of Prunus mume after liquor manufacturing were determined in a chicken breast meat system. When PM was added to chicken breast meat, 2-thiobarbituric acid-reactive substances (TBARS) value at day 3 was decreased by about $25\%$ compared to control meat without PM. PM did not significantly affect the color of chicken meat compared to the control. The amounts of volatile aldehydes and hydrocarbons were decreased by the addition of PM. Hexanal was the predominant volatile compound in the control, accounting for the majority of total volatiles; PM reduced the amount of hexanal to $81\%$of that in the control meat at 3 days.
( Sang Hee Lee ),( Min Ji Kim ),( Eun Jung Jo ),( Jung Seop Eom ),( Jeong Ha Mok ),( Mi Hyun Kim ),( Ki Uk Kim ),( Hye Kyung Park ),( Min Ki Lee ),( Kwang Ha Lee ) 대한결핵 및 호흡기학회 2014 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.118 No.-
Background: Currently, patients requiring ventilator care for more than 96 h are defined as undergoing prolonged acute mechanical ventilation (PAMV), and the number of such patients is expected to increase. We evaluated the clinical factors related to a poor prognosis by analyzing patients requiring PAMV in the medical intensive care unit (ICU) of a university-affiliated tertiary care hospital in Korea. Methods: We retrospectively analyzed data collected from March 2008 to February 2013. During the study period, 311 patients (41%) were categorized as on PAMV. We analyzed the prognostic factors on day 28 using clinical data gathered from the medical records on day 4 of mechanical ventilation (MV). Results: The median age of the enrolled patients was 67 [interquartile range (IQR) 59-75] years and 223 (71.7%) were male. The 28-day mortality rate after ICU admission was 34.7%. The most common underlying comorbidity was chronic lung disease (31.5%). The median ICU and hospital stays were 15 (IQR 9-27) and 26 (IQR 15-50) days, respectively. The median Acute Physiology and Chronic Health Evaluation and Sequential Organ Failure Assessment scores on the admission day were 17 (IQR 13-21) and 5 (IQR 3-6), respectively. Four variables on day 4 of MV (neuromuscular blocker required [hazard ratio (HR) 2.432, 95% confidence interval (CI) 1.337-4.422; p=0.004], vasopressor required [HR 2.312, 95% CI 1.258-4.248; p=0.007], hemodialysis required [HR 1.913, 95% CI 1.018-3.595; p=0.044], and body mass index = 21 [HR 1.827, 95% CI 1.015-3.288; p=0.044]) were independent factors associated with mortality based on a Cox proportional hazards model that excluded patients (n=12) with a do-not-resuscitate order given before day 4. Conclusions: Four clinical factors on day 4 of MV appear to indicate a poor prognosis in patients with PAMV: vasopressor required, neuromuscular blocker required, hemodialysis required, and body mass index = 21.
( Sang Hee Lee ),( Eun Jung Jo ),( Jung Seop Eom ),( Jeong Ha Mok ),( Mi Hyun Kim ),( Kwangha Lee ),( Ki Uk Kim ),( Hye Kyung Park ),( Chang Hun Lee ),( Yeong Dae Kim ),( Min Ki Lee ) 대한결핵 및 호흡기학회 2015 Tuberculosis and Respiratory Diseases Vol.78 No.4
Background: There have been various results from studies concerning the predictors of recurrence in early-stage nonsmall cell lung cancer (NSCLC). Therefore, an accurate assessment is needed to guide effective adjuvant therapy. We investigated the predictors of a recurrence in patients with resected, early-stage NSCLC and the risk factors associated with locoregional or distant recurrence. Methods: This retrospective study was conducted on patients at the Pusan National University Hospital from January 2006 to December 2011. Patients with pathological stages I or II were included in this study, as based on the seventh edition TNM staging system. Multivariate Cox proportional hazard models were used to identify factors associated with recurrence. Results: Two hundred and forty-nine patients were included. Among them, 180 patients were stage I, and 69 were stage II. Overall, by multivariate analysis, the independent factors associated with a 5-year total recurrence were the presence of visceral pleural invasion (VPI) (p=0.018) and maximal standardized uptake values (SUVs) of tumors on positron emission tomography (PET) >4.5 (p=0.037). The VPI was the only independent risk factor associated with both locoregional and distant recurrence, in the analysis of the patterns of tumor recurrence and their risk factors. In the subgroup analysis of stage I patients, three variables (male, VPI and resection margin positive) were significantly associated with a 5-year recurrence. Conclusion: The independent factors associated with postoperative recurrence in early-stage NSCLC were as follows: PET SUV >4.5 and the presence of VPI. For patients with those factors adjuvant therapy should be recommended as a more efficacious treatment.
( Sang Hee Lee ),( Min Ji Kim ),( Eun Jung Jo ),( Jung Seop Eom ),( Jeong Ha Mok ),( Mi Hyun Kim ),( Ki Uk Kim ),( Hye Kyung Park ),( Min Ki Lee ),( Kwang Ha Lee ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Currently, patients requiring ventilator care for more than 96 h are de- fined as undergoing prolonged acute mechanical ventilation (PAMV), and the number of such patients is expected to increase. We evaluated the clinical factors related to a poor prognosis by analyzing patients requiring PAMV in the medical intensive care unit (ICU) of a university-affiliated tertiary care hospital in Korea. Methods: We retrospectively analyzed data collected from March 2008 to February 2013. During the study period, 311 patients (41%) were categorized as on PAMV. We analyzed the prognostic factors on day 28 using clinical data gathered from the medical records on day 4 of mechanical ventilation (MV). Results: The median age of the enrolled patients was 67 [interquartile range (IQR) 59-75] years and 223 (71.7%) were male. The 28-day mortality rate after ICU admission was 34.7%. The most common underlying comorbidity was chronic lung disease (31.5%). The median ICU and hospital stays were 15 (IQR 9-27) and 26 (IQR 15-50) days, respectively. The median Acute Physiology and Chronic Health Evaluation and Sequential Organ Failure Assessment scores on the admission day were 17 (IQR 13-21) and 5 (IQR 3-6), respectively. Four variables on day 4 of MV (neuromuscular blocker required [hazard ratio (HR) 2.432, 95% confidence interval (CI) 1.337-4.422; p=0.004], vasopressor required [HR 2.312, 95% CI 1.258-4.248; p=0.007], hemodialysis required [HR 1.913, 95% CI 1.018-3.595; p=0.044], and body mass index = 21 [HR 1.827, 95% CI 1.015-3.288; p=0.044]) were independent factors associated with mortality based on a Cox proportional hazards model that excluded patients (n=12) with a do-not-resuscitate order given before day 4. Conclusions: Four clinical factors on day 4 of MV appear to indicate a poor prognosis in patients with PAMV: vasopressor required, neuromuscular blocker required, hemodialysis required, and body mass index = 21.